November 19, 2026
Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma
November 19, 2026
JOYY Reports Third Quarter 2026 Unaudited Financial Results
November 19, 2026